Rodman & Renshaw Hikes Price Target On Adventrx Pharmaceuticals (ANX) to $16
ANX Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rodman & Renshaw raised their price target on Adventrx Pharmaceuticals (NYSE: ANX) from $4.50 to $16 while maintaining their Market Outperform rating.
Shares are on the move following the price target hike. Last trading up 9.7% to $2.60.
For more ratings news on Adventrx Pharmaceuticals click here and for the rating history of Adventrx Pharmaceuticals click here.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Shares are on the move following the price target hike. Last trading up 9.7% to $2.60.
For more ratings news on Adventrx Pharmaceuticals click here and for the rating history of Adventrx Pharmaceuticals click here.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Auriga Reiterates a 'Buy' on DSW Inc. (DSW); Raising Estimates and PT After Great Q1
- UBS Maintains a 'Buy' on Express Inc. (EXPR); A Misstep, But Still A Consistent Performer
- UBS Cuts Price Target and Estimates on Analog Devices (ADI); Good Q2, But Slowing Growth in N-T
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Rodman & RenshawComments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Re: Treasurer
allengodwinbis on Aug 29, 2011 02:05 AMMark as Spam
Thanks for sharing this information.
_______
Allen
Anchor Text